[{"id":"74915413-c151-4ff8-ac18-adfbd918fb7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06000787","created_at":"2023-08-21T15:09:02.705Z","updated_at":"2025-02-25T14:09:59.668Z","phase":"","brief_title":"MCT for the Harvard/UCSF ROBIN Center","source_id_and_acronym":"NCT06000787","lead_sponsor":"Brigham and Women's Hospital","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 09/19/2023","start_date":" 09/19/2023","primary_txt":" Primary completion: 08/31/2028","primary_completion_date":" 08/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-17"},{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2025-02-25T15:10:35.328Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"76e5fabc-947c-4440-ba90-48fba05bcaa1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01850888","created_at":"2021-01-18T08:15:43.798Z","updated_at":"2025-02-25T16:51:18.108Z","phase":"","brief_title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","source_id_and_acronym":"NCT01850888","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" IL6 • IL2","pipe":"","alterations":" ","tags":["IL6 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Azedra (iobenguane I 131)"],"overall_status":"Suspended","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-04"},{"id":"8c64ed6b-f5aa-4d8b-8883-487500c8bd4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01370330","created_at":"2021-01-18T05:36:49.021Z","updated_at":"2024-07-02T16:34:59.602Z","phase":"","brief_title":"131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol","source_id_and_acronym":"NCT01370330","lead_sponsor":"Kieuhoa Vo","biomarkers":" IL6 • CD34","pipe":"","alterations":" ","tags":["IL6 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-06-03"},{"id":"03d20bb1-3102-40cf-b03f-65ae64111bd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00107289","created_at":"2021-01-18T00:21:00.478Z","updated_at":"2024-07-02T16:35:15.417Z","phase":"Phase 2","brief_title":"Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma","source_id_and_acronym":"NCT00107289","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-03-11"},{"id":"3774dfa5-925b-409c-945c-df7675dbbddb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01175356","created_at":"2021-01-18T04:41:27.816Z","updated_at":"2024-07-02T16:35:24.567Z","phase":"Phase 1","brief_title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","source_id_and_acronym":"NCT01175356","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • busulfan • Azedra (iobenguane I 131) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 10/04/2010","start_date":" 10/04/2010","primary_txt":" Primary completion: 09/28/2016","primary_completion_date":" 09/28/2016","study_txt":" Completion: 09/28/2024","study_completion_date":" 09/28/2024","last_update_posted":"2024-01-04"},{"id":"3dbe8d1e-d184-444c-b1e6-997402bbb8ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT00509353","created_at":"2021-01-18T01:49:55.285Z","updated_at":"2024-07-02T16:35:29.785Z","phase":"Phase 1","brief_title":"N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma","source_id_and_acronym":"NCT00509353","lead_sponsor":"Children's Hospital Los Angeles","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • vincristine • Azedra (iobenguane I 131)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2023-11-09"},{"id":"5b063683-e06b-4699-9a29-422d240e8a26","acronym":"","url":"https://clinicaltrials.gov/study/NCT03332667","created_at":"2021-07-05T17:09:29.759Z","updated_at":"2024-07-02T16:35:34.961Z","phase":"Phase 1","brief_title":"MIBG With Dinutuximab +/- Vorinostat","source_id_and_acronym":"NCT03332667","lead_sponsor":"New Approaches to Neuroblastoma Therapy Consortium","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat) • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/12/2018","start_date":" 09/12/2018","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-10-03"},{"id":"f0bfa210-af4d-4908-8483-ac1408f8c7ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT01838187","created_at":"2021-01-18T08:11:06.670Z","updated_at":"2024-07-02T16:35:39.738Z","phase":"","brief_title":"Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma","source_id_and_acronym":"NCT01838187","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat) • Azedra (iobenguane I 131)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-17"},{"id":"996bba9a-762c-4c0d-a3e9-1b3284ea0005","acronym":"","url":"https://clinicaltrials.gov/study/NCT03044977","created_at":"2021-02-11T16:53:19.964Z","updated_at":"2024-07-02T16:35:39.819Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors","source_id_and_acronym":"NCT03044977","lead_sponsor":"David Bushnell","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR positive • SSTR2 positive","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/07/2017","start_date":" 05/07/2017","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-08-16"},{"id":"7c6e50e7-c4e9-45ba-8929-8ebd79639059","acronym":"","url":"https://clinicaltrials.gov/study/NCT01163383","created_at":"2021-01-18T04:38:10.485Z","updated_at":"2024-07-02T16:35:43.363Z","phase":"","brief_title":"131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol","source_id_and_acronym":"NCT01163383","lead_sponsor":"John Maris","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-07-12"},{"id":"41f7ba3d-5c57-406c-bb6a-487d9c379f92","acronym":"","url":"https://clinicaltrials.gov/study/NCT03015844","created_at":"2021-01-18T14:50:29.693Z","updated_at":"2024-07-02T16:35:50.706Z","phase":"","brief_title":"A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma","source_id_and_acronym":"NCT03015844","lead_sponsor":"Northwell Health","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-04-13"},{"id":"5e43e0cb-747f-4862-bd50-2f5e4aa656c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01590680","created_at":"2021-01-18T06:47:28.360Z","updated_at":"2024-07-02T16:35:54.617Z","phase":"","brief_title":"Expanded Access Protocol Using 131I-MIBG","source_id_and_acronym":"NCT01590680","lead_sponsor":"Jubilant DraxImage Inc.","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-02-28"},{"id":"d08d28eb-68cd-49ac-a524-9a247cdc79ba","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT03561259","created_at":"2021-01-18T17:31:39.370Z","updated_at":"2024-07-02T16:35:55.348Z","phase":"Phase 2","brief_title":"A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects","source_id_and_acronym":"NCT03561259 - OPTIMUM","lead_sponsor":"Jubilant DraxImage Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Zolinza (vorinostat) • Azedra (iobenguane I 131)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/21/2019","start_date":" 10/21/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-02-16"},{"id":"3bea83cb-bd9d-4252-abbf-b6bb189c85ec","acronym":"N2011-01","url":"https://clinicaltrials.gov/study/NCT02035137","created_at":"2021-01-18T09:20:07.243Z","updated_at":"2024-07-02T16:36:09.187Z","phase":"Phase 2","brief_title":"131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat","source_id_and_acronym":"NCT02035137 - N2011-01","lead_sponsor":"New Approaches to Neuroblastoma Therapy Consortium","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • vincristine • Zolinza (vorinostat) • Azedra (iobenguane I 131)"],"overall_status":"Completed","enrollment":" Enrollment 114","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/26/2021","primary_completion_date":" 02/26/2021","study_txt":" Completion: 02/26/2021","study_completion_date":" 02/26/2021","last_update_posted":"2022-06-08"},{"id":"5f0208c0-5fab-498a-8596-1815b86c70c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03649438","created_at":"2021-01-18T17:54:43.427Z","updated_at":"2024-07-02T16:36:11.681Z","phase":"","brief_title":"131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma","source_id_and_acronym":"NCT03649438","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" IL6 • CD34 • IL2","pipe":"","alterations":" ","tags":["IL6 • CD34 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Azedra (iobenguane I 131)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-04-21"},{"id":"cc830e4f-0e5a-48e2-b194-17c4a05e0b3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01377532","created_at":"2021-01-18T05:38:44.746Z","updated_at":"2024-07-02T16:36:45.316Z","phase":"","brief_title":"Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma","source_id_and_acronym":"NCT01377532","lead_sponsor":"University of California, San Francisco","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-05-06"},{"id":"32bfbd91-ee7b-40ce-a340-2c54f851c515","acronym":"","url":"https://clinicaltrials.gov/study/NCT01313936","created_at":"2021-01-18T05:20:58.989Z","updated_at":"2024-07-02T16:37:00.119Z","phase":"Phase 1","brief_title":"High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma","source_id_and_acronym":"NCT01313936","lead_sponsor":"University of California, San Francisco","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • vincristine • Azedra (iobenguane I 131)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 05/01/2014","study_completion_date":" 05/01/2014","last_update_posted":"2019-04-29"},{"id":"275be695-4a36-4a4c-9d5c-416ed14441d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01413503","created_at":"2021-01-18T05:49:07.831Z","updated_at":"2024-07-02T16:37:06.769Z","phase":"Phase 2","brief_title":"A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors","source_id_and_acronym":"NCT01413503","lead_sponsor":"University of California, San Francisco","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/1991","start_date":" 05/01/1991","primary_txt":" Primary completion: 09/06/2007","primary_completion_date":" 09/06/2007","study_txt":" Completion: 05/01/2009","study_completion_date":" 05/01/2009","last_update_posted":"2018-09-18"}]